<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Vox Sang</span><span class="iso-abbrev" title="iso-abbrev">Vox Sang</span><span class="doi" title="doi">10.1111/(ISSN)1423-0410</span><span class="publisher-id" title="publisher-id">VOX</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Vox Sanguinis</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0042-9007</span><span class="issn-epub" tagx="issn" title="issn-epub">1423-0410</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley and Sons Inc.</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Hoboken</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7264781">7264781</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1111/vox.12939">10.1111/vox.12939</a></span><span class="publisher-id" title="publisher-id">VOX12939</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Commentary</span>: <span class="subject" title="subject">Commentary</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Points to consider in the preparation and transfusion of COVIDâ€�19 convalescent plasma</div> <div class="alt-title" title="alt-title">
COVIDâ€�10 convalescent plasma</div> <div class="alt-title" title="alt-title">
J. Epstein and T. Burnouf</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Epstein</span><span class="given-names" tagx="given-names" title="given-names">Jay</span></span><a href="#vox12939-aff-0001"><sup>1</sup></a><span class="address" title="address"><span class="email" tagx="email" title="email">Jay.Epstein@fda.hhs.gov</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Burnouf</span><span class="given-names" tagx="given-names" title="given-names">Thierry</span></span><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-0507-9243</span><a href="#vox12939-aff-0002"><sup>2</sup></a></span></div><span class="citation_author_institution" id="vox12939-aff-0001">[1], <span class="institution" title="institution">US Food and Drug Administration</span><span class="city" tagx="city" title="city">Silver Spring</span><span class="named-content" title="named-content">MD</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="vox12939-aff-0002">[2], <span class="named-content" title="named-content">Graduate Institute of Biomedical Materials and Tissue Engineering</span><span class="named-content" title="named-content">College of Biomedical Engineering</span><span class="institution" title="institution">Taipei Medical University</span><span class="city" tagx="city" title="city">Taipei</span><span class="country" tagx="country" title="country">Taiwan</span></span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span><i>Correspondence:</i> Jay Epstein, US Food and Drug Administration, Silver Spring, MD, USA<br /><br /> Email: <span class="email" tagx="email" title="email">Jay.Epstein@fda.hhs.gov</span><br /><br /></div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-5-5</span></span><span class="elocation-id" tagx="elocation-id" title="elocation-id">10.1111/vox.12939</span><span class="history" title="history"><span class="received" title="received">received: 2020-4-16</span><span class="accepted" title="accepted">accepted: 2020-4-19</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</span></span></div><a class="self-uri" href="file:VOX-9999-na.pdf" title="self-uri">file:VOX-9999-na.pdf</a><div class="kwd-group"> <div class="kwd" title="kwd">
convalescent plasma</div> <div class="kwd" title="kwd">
coronavirus</div> <div class="kwd" title="kwd">
COVIDâ€�19</div> <div class="kwd" title="kwd">
SARSâ€�CoVâ€�2</div> <div class="kwd" title="kwd">
transfusion</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="source-schema-version-number" value="2.0" /> <meta name="edited-state" value="corrected-proof" /> <meta name="details-of-publishers-convertor" value="Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:02.06.2020" /> </div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"> <div class="title" tagx="title" title="title">
Introduction</div> <p>This document provides the perspective as of April 2020 of the Working Party on Global Blood Safety of the International Society of Blood Transfusion on use of COVIDâ€�19 convalescent plasma as an experimental treatment for COVIDâ€�19.Â The document addressesÂ the following important factors to have in mind when considering this treatment: (A) eligibility criteria of convalescent COVIDâ€�19 patients to donate whole blood or plasma; (B) preâ€�screening and preâ€�donation testing of convalescent COVIDâ€�19 donors; (C) criteria for collection of COVIDâ€�19 plasma; (D) postâ€�donation treatment of plasma; and (E) recommendations for plasma transfusion.</p> </div> <div class="importantnotices" title="sec"> <div class="title" tagx="title" title="title">
Important notices</div> <p> </p><ul> <li> <p>Because the safety and efficacy of convalescent COVIDâ€�19 plasma as a treatment for COVIDâ€�19 are unproven at this time, clinical use of this product should be managed as an experimental therapy consistent with ethical and legal safeguards (informed consent of donors and patients, institutional approval, special labelling as an investigational product, compliance with applicable regulatory requirements).</p> </li> <li> <p>Ideally, COVIDâ€�19 plasma should be used in the context of an organized research study designed to determine its safety and efficacy in comparison with standard of care or other therapeutic interventions. Even if used empirically, it is vital to ensure monitoring of patient outcomes including clinical and laboratory indicators of safety and efficacy to maximize the knowledge that might be gained.</p> </li> <li> <p>Collection and retention of blood specimens from both donors and recipients (preâ€� and postâ€�treatment) should be performed to permit retrospective determination of the characteristics of an effective product and dosage regimen, and the characteristics of patients most likely to benefit.</p> </li> <li> <p>General information on the rationale and approach to use of convalescent plasma in virus epidemics can be found in the â€˜WHO Blood Regulators Network Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging VirusÂ (2017)â€™Â [<a href="#vox12939-bib-0001">1</a>].</p> </li> </ul> <p /> <p>Intentional collection of convalescent plasma should be performed only by apheresis in order to avoid unnecessary red cell loss in the donor and to optimize the volume of plasma that can be generated for investigational use. In instances of routine whole blood donation by a previously infected person who meets current suitability criteria, COVIDâ€�19 convalescent plasma can be prepared by component separation and considered for investigational use if not critically needed for general patient care. Transfusion of whole blood to provide convalescent plasma should be avoided unless use of whole blood is clinically indicated.</p> </div> <div class="keypoints" title="sec"> <div class="title" tagx="title" title="title">
Key points</div> <p> </p><ul> <li> <p>Eligibility of convalescent COVIDâ€�19 patients to donate whole blood or plasma should be based on: </p> <ul> <li> <p>Confirmation of previous infection with SARSâ€�CoVâ€�2 by a record of a validated diagnostic test at the time of illness.</p> </li> <li> <p>An interval of at least 14Â days after full recovery.</p> </li> <li> <p>Standard selection criteria for whole blood or plasma donation according to local requirements and standards (age, weight, collection frequency, vital signs, freedom from deferral criteria) in line with â€˜WHO Blood Regulators Network (BRN): Donor selection in case of pandemic situationsâ€™ [<a href="#vox12939-bib-0002">2</a>].</p> </li> <li> <p>Nonâ€�reactivity of blood samples for transfusionâ€�transmitted infections including HIV, HBV, HCV, syphilis (for whole blood) and locally transmitted infections using approved serological and/or nucleic acid tests, consistent with local requirements for collection of blood components for transfusion.</p> </li> <li> <p>To avoid the risk of transfusionâ€�related acute lung injury (TRALI), preference should be given to use of plasma from male donors or from female donors who have never been pregnant including abortions. This measure lowers the possibility of presence in the plasma of the antibodies to HLA or granulocyte antigens that cause TRALI. Testing for these antibodies in female donors who have been pregnant is desirable as an added precaution where feasible.Â TRALI occurs within 6Â h after transfusion of implicated plasma and can be severe [<a href="#vox12939-bib-0003">3</a>].</p> </li> </ul> </li> <li> <p>Preâ€�screening and preâ€�donation testing of convalescent COVIDâ€�19 donors </p> <ul> <li> <p><i>Recov</i>ery from COVIDâ€�19 infection should be confirmed through: </p> <ul> <li> <p>Physical examination of the donor to establish good health including absence of fever and respiratory symptoms.</p> </li> <li> <p>If plasma is collected prior to 28Â days after full recovery from illness, then confirmation of the resolution of the infection should be obtained through demonstration of two nonâ€�reactive nucleic acid tests (NAT) for SARSâ€�CoVâ€�2 performed at an interval of at least 24Â h on nasopharyngeal swabs.</p> </li> <li> <p>Viral inactivation of convalescent plasma is encouraged to address residual risks of known transfusionâ€�transmissible viruses in an experimental product.</p> </li> <li> <p>The approximate date of COVIDâ€�19 infection, history of symptoms, treatments received and date of resolution of all symptoms documented and traceable.</p> </li> <li> <p>When feasible, the total and neutralizing titres of antiâ€�SARSâ€�CoVâ€�2 antibodies should be determined as part of product characterization before use. Furthermore, donor blood/serum/plasma samples should be saved frozen at âˆ’80Â°C for retrospective testing and further scientific investigations.</p> </li> </ul> </li> </ul> </li> <li> <p>Criteria for collection of COVIDâ€�19 plasma. </p> <ul> <li> <p>Performed in certified blood establishments (or under exceptional circumstances hospitals and other healthcare facilities routinely engaged in performing whole blood collection with plasma separation and/or apheresis procedures) by appropriately trained staff.</p> </li> <li> <p>Use only of legally authorized blood collection or plasmapheresis equipment under standard operating procedures.</p> </li> <li> <p>Supervision of the collection process by trained staff.</p> </li> <li> <p>Volume of plasma to be collected: at least 200â€"600Â ml (without anticoagulant) based on the procedure and regulatory limits.</p> </li> <li> <p>Plasma units intended for use as convalescent plasma should be clearly labelled (ISBT128 product description codes for convalescent plasma are available for establishments using the ISBT128 information standard).</p> </li> <li> <p>The first plasma donation can be followed by further donations at a frequency compliant with local regulations and taking into full account the health status of the donorÂ including monitoring of serum protein levels. In many jurisdictions, the interval between apheresis plasma donations of 600Â ml or more should not be less than 7Â days and that between whole blood donations should be at least 8Â weeks.</p> </li> </ul> </li> <li> <p>Postâ€�donation treatment of plasma: </p> <ul> <li> <p>Where feasible, pathogen inactivation of plasma using a licensed technology is highly desirable to control residual risks of transfusionâ€�transmitted infectious diseases and to allay concern about possible superinfections with SARSâ€�CoVâ€�2.</p> </li> <li> <p>Freezing as soon as possible at âˆ’20Â°C or preferably colder and stored frozen until administration.</p> </li> <li> <p>Convalescent plasma collected from donors who do not fulfil postâ€�COVIDâ€�19 suitability criteria for blood donation should be stored separately from other blood products in inventory.</p> </li> <li> <p>Plasma sample aliquots should be taken for archiving at âˆ’80Â°C and future potential scientific investigations.</p> </li> </ul> </li> <li> <p>Recommendations for plasma transfusion: </p> <ul> <li> <p>Follow standard hospital procedures and recommendations for thawing and transfusion of plasma.</p> </li> <li> <p>It is crucial to ensure ABO compatibility between the donor and the recipient.</p> </li> <li> <p>Transfusion of plasma from at least two donors may be therapeutically beneficial to achieve more effective immune protection from delivery of diverse antibodies.</p> </li> <li> <p>In the absence of published peerâ€�reviewed reports of transfusion of convalescent COVIDâ€�19 plasma, patients could receive an initial dose of 200Â ml, followed by one or two additional doses of 200Â ml according to disease severity and tolerance of the infusions.</p> </li> <li> <p>Blood/serum/plasma samples of the recipient prior to and after transfusion should be taken for future potential scientific investigations.</p> </li> </ul> </li> </ul> <p /> </div> <div class="disclaimer" title="sec"> <div class="title" tagx="title" title="title">
Disclaimer</div> <p>Jay Epsteinâ€™s contributions to this article reflect his own views and should not be construed to represent FDAâ€™s views or policies.</p> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgements</div> <p>This documentÂ was endorsed by the Organizing Committee of the Working Party on Global Blood Safety of the International Society of Blood Transfusion: W. Martin Smid (chair), Thierry Burnouf, Jay Epstein; Hany Kamel, Cees Smit Sibinga, Daniel Somuah, Susan Stramer and Silvano Wendel. The authors express their appreciation to Diana Teo, Michael Busch and Micha Nuebling for their comments on the draft document.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="vox12939-bib-0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: WHO Blood Regulators Network</span> : <span class="mixed-article-title" title="mixed-article-title">Position paper on use of convalescent plasma, serum or immune globulin concentrates as an element in response to an emerging virus</span><span class="year" tagx="year" title="year">2017</span><a href="https://www.who.int/bloodproducts/brn/2017_BRN_PositionPaper_ConvalescentPlasma.pdf?ua=1">https://www.who.int/bloodproducts/brn/2017_BRN_PositionPaper_ConvalescentPlasma.pdf?ua=1</a> [Last accessed 6 May 2020]</span></li> <li tag="ref"><a name="vox12939-bib-0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: WHO Blood Regulators Network (BRN)</span> : <span class="mixed-article-title" title="mixed-article-title">Donor selection in case of pandemic situations</span><span class="year" tagx="year" title="year">2007</span><a href="https://www.who.int/bloodproducts/brn/DonorSelectionincaseofPandemicSituations.pdf?">https://www.who.int/bloodproducts/brn/DonorSelectionincaseofPandemicSituations.pdf?</a> [Last accessed 6 May 2020]</span></li> <li tag="ref"><a name="vox12939-bib-0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Toy</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>: <span class="mixed-article-title" title="mixed-article-title">Update on transfusionâ€�related acute lung injury</span>. <span class="source" tagx="source" title="source">Clin Adv Hematol Oncol</span><span class="year" tagx="year" title="year">2019</span>; <span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">378</span>â€"<span class="lpage" tagx="lpage" title="lpage">381</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31449502">31449502</a></span></span></li> </ul> </div> </div>  </body></html>